SCHEMBL7146167

SCHEMBL7146167

Cc1cccc(NS(=O)(=O)CCCSc2nc3cc(C)ccc3s2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 12/20 0.41
HTT P42858 3/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
HSP90AA1 P07900 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
IDO1 P14902 1/20 0.39
CYP3A4 P08684 2/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148116 0.97 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7146699 0.94 ALDH1A1 (0.47) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7147570 0.92 ALDH1A1 (0.54) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7153246 0.90 ALDH1A1 (0.43) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7147065 0.90 LMNA (0.46) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7149819 0.89 ALDH1A1 (0.53) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7153984 0.88 LMNA (0.46) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7153185 0.87 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7153276 0.87 MAPT (0.43) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7151043 0.86 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885LMNA 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.